Rajan Sharma's questions to Genmab A/S (GMAB) leadership • Q1 2025
Question
Rajan Sharma from Goldman Sachs asked for clarification on the discrepancy between the company's guided 2026 readout for the EPCORE DLBCL-2 trial and the mid-2027 primary completion date listed on clinicaltrials.gov.
Answer
CMO Tahamtan Ahmadi advised against using clinicaltrials.gov as the definitive source for timelines. He explained that study readouts are event-driven and that patient accrual for this trial was 'significantly faster than initially projected,' which could lead to results being available earlier than the date listed on the public registry.